Literature DB >> 28343297

Association of the CX3CR1-V249I Variant with Neurofibrillary Pathology Progression in Late-Onset Alzheimer's Disease.

Alan López-López1, Ellen Gelpi2, Diana Maria Lopategui1,3, Jose M Vidal-Taboada4,5.   

Abstract

Neuroinflammation and microglial dysfunction have a prominent role in the pathogenesis of late-onset Alzheimer's disease (LOAD). CX3CR1 is a microglia-specific gene involved in microglia-neuron crosstalk and neuroinflammation. Numerous evidence show the involvement of CX3CR1 in AD. The aim of this study was to investigate if some functional genetic variants of this gene could influence on LOAD's outcome, in a neuropathologically confirmed Spanish cohort. We designed an open, pragmatic, case-control retrospective study including a total of 475 subjects (205 pathologically confirmed AD cases and 270 controls). We analyzed the association of the two CX3CR1 functional variants (V249I, rs3732379; and T280M, rs3732378) with neurofibrillary pathology progression rate according to Braak's staging system, age at onset (AAO), survival time, and risk of suffering LOAD. We found that individuals heterozygous for CX3CR1-V249I presented a lower neurofibrillary pathology stage at death (OR = 0.42, 95%CI [0.23, 0.74], p = 0.003, adj-p = 0.013) than the other genotypes. Eighty percent of the subjects homozygous for 249I had higher neurofibrillary pathology progression (Braak's stage VI). Moreover, homozygosis for 280M and 249I could be associated with a higher AAO in the subgroups of AD with Lewy bodies and without Lewy bodies. These CX3CR1 genetic variants could represent new modifying factors of pathology progression and age at onset in LOAD. These results provide further evidence of the involvement of CX3CR1 pathway and microglia/macrophages in the pathogenesis of LOAD.

Entities:  

Keywords:  Age at onset; Alzheimer disease; CX3CR1; Fractalkine receptor (OMIM 601470); Modifying gene; Progression

Mesh:

Substances:

Year:  2017        PMID: 28343297     DOI: 10.1007/s12035-017-0489-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  47 in total

Review 1.  Neuroinflammation and synaptic loss.

Authors:  Jagadeesh S Rao; Matthew Kellom; Hyung-Wook Kim; Stanley I Rapoport; Edmund A Reese
Journal:  Neurochem Res       Date:  2012-02-07       Impact factor: 3.996

Review 2.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

3.  The Lewy body variant of Alzheimer disease.

Authors:  L A Hansen
Journal:  J Neural Transm Suppl       Date:  1997

Review 4.  Mechanisms underlying inflammation in neurodegeneration.

Authors:  Christopher K Glass; Kaoru Saijo; Beate Winner; Maria Carolina Marchetto; Fred H Gage
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

5.  Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease.

Authors:  Laura Parkkinen; Hilkka Soininen; Irina Alafuzoff
Journal:  J Neuropathol Exp Neurol       Date:  2003-04       Impact factor: 3.685

6.  Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease.

Authors:  Alain R Simard; Denis Soulet; Genevieve Gowing; Jean-Pierre Julien; Serge Rivest
Journal:  Neuron       Date:  2006-02-16       Impact factor: 17.173

Review 7.  Myeloid cells in Alzheimer's disease: culprits, victims or innocent bystanders?

Authors:  Melanie Meyer-Luehmann; Marco Prinz
Journal:  Trends Neurosci       Date:  2015-10       Impact factor: 13.837

Review 8.  Neuroinflammation in Alzheimer's disease.

Authors:  Michael T Heneka; Monica J Carson; Joseph El Khoury; Gary E Landreth; Frederic Brosseron; Douglas L Feinstein; Andreas H Jacobs; Tony Wyss-Coray; Javier Vitorica; Richard M Ransohoff; Karl Herrup; Sally A Frautschy; Bente Finsen; Guy C Brown; Alexei Verkhratsky; Koji Yamanaka; Jari Koistinaho; Eicke Latz; Annett Halle; Gabor C Petzold; Terrence Town; Dave Morgan; Mari L Shinohara; V Hugh Perry; Clive Holmes; Nicolas G Bazan; David J Brooks; Stéphane Hunot; Bertrand Joseph; Nikolaus Deigendesch; Olga Garaschuk; Erik Boddeke; Charles A Dinarello; John C Breitner; Greg M Cole; Douglas T Golenbock; Markus P Kummer
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

Review 9.  Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration.

Authors:  V Hugh Perry; Jessica Teeling
Journal:  Semin Immunopathol       Date:  2013-06-04       Impact factor: 9.623

Review 10.  CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection.

Authors:  Peiqing Chen; Wenjuan Zhao; Yanjie Guo; Juan Xu; Ming Yin
Journal:  Biomed Res Int       Date:  2016-06-27       Impact factor: 3.411

View more
  8 in total

Review 1.  Microglia-Mediated Neuroprotection, TREM2, and Alzheimer's Disease: Evidence From Optical Imaging.

Authors:  Carlo Condello; Peng Yuan; Jaime Grutzendler
Journal:  Biol Psychiatry       Date:  2017-10-14       Impact factor: 13.382

2.  CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer's disease.

Authors:  Shweta S Puntambekar; Miguel Moutinho; Peter Bor-Chian Lin; Vaishnavi Jadhav; Danika Tumbleson-Brink; Ananya Balaji; Martin Alvarado Benito; Guixiang Xu; Adrian Oblak; Cristian A Lasagna-Reeves; Gary E Landreth; Bruce T Lamb
Journal:  Mol Neurodegener       Date:  2022-06-28       Impact factor: 18.879

3.  Genetic disruption of fractalkine signaling leads to enhanced loss of cochlear afferents following ototoxic or acoustic injury.

Authors:  Tejbeer Kaur; Kevin K Ohlemiller; Mark E Warchol
Journal:  J Comp Neurol       Date:  2017-12-17       Impact factor: 3.215

4.  Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model.

Authors:  Julie Vérité; Guylène Page; Marc Paccalin; Adrien Julian; Thierry Janet
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

5.  CX3CR1-deficient microglia shows impaired signalling of the transcription factor NRF2: Implications in tauopathies.

Authors:  Sara Castro-Sánchez; Ángel J García-Yagüe; Sebastian Kügler; Isabel Lastres-Becker
Journal:  Redox Biol       Date:  2019-02-06       Impact factor: 11.799

Review 6.  The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders.

Authors:  Paulina Pawelec; Malgorzata Ziemka-Nalecz; Joanna Sypecka; Teresa Zalewska
Journal:  Cells       Date:  2020-10-13       Impact factor: 6.600

Review 7.  Aβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer's Disease.

Authors:  Yuanxin Zhao; Buhan Liu; Jian Wang; Long Xu; Sihang Yu; Jiaying Fu; Xiaoyu Yan; Jing Su
Journal:  Biomedicines       Date:  2022-07-27

8.  Computational study of the structural ensemble of CC chemokine receptor type 5 (CCR5) and its interactions with different ligands.

Authors:  Guillermo Goode-Romero; Laura Dominguez
Journal:  PLoS One       Date:  2022-10-17       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.